PUNE, India, January 15, 2016 /PRNewswire/ --
The Vitiligo - Pipeline Review, H2 2015 report helps enhance decision making capabilities and create effective counter strategies to gain competitive advantage in vitiligo market. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
The report provides a snapshot of the global therapeutic landscape of Vitiligo. The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities and key players involved in the therapeutics development for Vitiligo and enlists all their major and minor projects summarizing all the dormant and discontinued pipeline projects. A review of the Vitiligo products under development by companies and universities/research institutes based on information derived from company and industry-specific sources, pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages, detailed assessment of monotherapy and combination therapy pipeline projects, coverage of the Vitiligo pipeline on the basis of target, MoA, route of administration and molecule type and latest news and deals relating related to pipeline products.
Complete report on H2 2015 pipeline review of Vitiligo, spread across 62 pages is available at http://www.reportsnreports.com/reports/457004-vitiligo-pipeline-review-h2-2015.html .
Company Profiles covered in this report include Ache Laboratorios Farmaceuticos S/A, Biocon Limited, Bristol-Myers Squibb Company and Clinuvel Pharmaceuticals Limited. Drugs Profiles discussed in this report cover abatacept, ACH-24, afamelanotide, Gene Therapy to Activate SOX9 for Vitiligo and Melanoma, itolizumab, SUN-0597 and VLRX-001.
This report provides comprehensive information on the therapeutic development for Vitiligo, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vitiligo and special features on late-stage and discontinued projects.
Order a copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=457004 .
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Vitiligo
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Vitiligo pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Another newly published market research titled Rubella - Pipeline Review, H2 2015 provides comprehensive information on the therapeutic development for Rubella, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rubella and special features on late-stage and discontinued projects. The report reviews key players involved in the therapeutics development for Rubella and enlists all their major & minor projects and key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities. Rubella Pipeline Review research report of 48 pages is available at http://www.reportsnreports.com/reports/457010-rubella-pipeline-review-h2-2015.html .
Explore more reports on pharmaceuticals market and other disease pipelines at http://www.reportsnreports.com/market-research/pharmaceuticals/ .
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
+ 1 888 391 5441
Connect With Us on:
Twitter: https: //twitter.com/marketsreports
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts